Lactucopicrina

Lactucopicrin: A Comprehensive Reference

1. Identity and Chemical Characterization

Names and Classification

Lactucopicrin, also known as lactupicrin or intybin, is a guaian-type sesquiterpene lactone with the molecular formula C₂₃H₂₂O₇ and a molecular weight of 410.4 g/mol, characterized by its bitter taste and presence in the latex of certain plants in the Asteraceae family. Its IUPAC-derived name describes the compound as a sesquiterpene lactone with a bitter flavor, and it is also registered under the synonym intybin. Its CAS registry number is 65725-11-3.

Lactucopicrin is a sesquiterpene lactone, meaning it is a 15-carbon compound derived from three isoprene units. It contains a lactone ring — a cyclic ester — that contributes to its reactivity. Specifically, it is classified as a 6,7-trans guaianolide sesquiterpene lactone. Guaianolides are characterized by a fused bicyclic framework consisting of a seven-membered and a five-membered ring. All sesquiterpene lactones contain a fused 5-membered lactone group (γ-lactone) with a carbonyl moiety at the alpha position.

Key Related Compounds

Lactucopicrin serves as a natural plant metabolite functionally related to lactucin and 4-hydroxyphenylacetic acid. The principal constitutive sesquiterpene lactones in lettuce and chicory are lactucin, 11β,13-dihydrolactucin, lactucopicrin (esterified lactucin), and 11β,13-dihydrolactucopicrin (esterified 11β,13-dihydrolactucin), in either free or glycosylated form. Structurally, lactucopicrin can be viewed as the 4-hydroxyphenylacetyl ester of lactucin, and its dihydro-derivative (11β,13-dihydrolactucopicrin) is a closely related analogue differing by hydrogenation of the exocyclic double bond on the lactone ring.

Light Sensitivity

Lactucopicrin is noted for its potent bitterness and light sensitivity, distinguishing it from other components in Lactuca species. This photosensitivity is practically significant: traditional and modern isolation procedures must be conducted under light-protected conditions to avoid degradation.

2. Natural Sources and Botanical Distribution

Primary Plant Sources

Lactucopicrin is a sesquiterpene lactone and is a component of lactucarium, derived from the plant Lactuca virosa (wild lettuce), as well as being found in some related plants such as Cichorium intybus. It is also found in dandelion coffee.

It is isolated primarily from species such as Lactuca virosa (wild lettuce), Lactuca sativa (cultivated lettuce), and Cichorium intybus (chicory), where it occurs at concentrations around 5 mg/g in lettuce latex. Lactucopicrin is also present in leafy vegetables such as chicory, curly escarole, and lettuce.

The most abundant sesquiterpene lactones isolated from the root of Cichorium intybus L. are lactucin, 8-deoxylactucin, 11(S),13-dihydro-8-deoxylactucin, lactucopicrin, 11(S),13-dihydrolactucopicrin, jacquinelin, crepidiaside B, and lactuside A. Sesquiterpene lactones are soluble, accumulating metabolites in Asteraceae, especially in chicory, and are mainly present in the latex.

The most abundant sesquiterpene lactones in chicory are lactucin (LC), 11β,13-dihydrolactucin (DHLC), lactucopicrin (LCP), and 11β,13-dihydrolactucopicrin (DHLCP). The concentration of lactucopicrin in lettuce can vary depending on the variety and growing conditions.

To most people, one of the most readily encountered aspects of sesquiterpene lactones is the bitterness they confer to foods such as chicory, where it is considered one of the main flavor aspects, but also in lettuce where it is considered detrimental to the taste.

Lactucarium: The Processed Form

Lactucarium is the dried, hardened milky latex exuded from the stems and leaves of certain wild lettuce species, primarily Lactuca virosa, a biennial herb native to regions including Europe and parts of Asia. This substance, often referred to as "lettuce opium," contains bioactive sesquiterpene lactones such as lactucin, lactucopicrin, and their derivatives, which contribute to its pharmacological effects.

3. Traditional and Historical Use

Ancient and Classical Traditions

Dioscorides described lettuce as sleep-inducing in De Materia Medica, and Pliny the Elder echoed this in Natural History. Later European herbalists such as Nicholas Culpeper categorized lettuce as cooling and soporific. Lettuce seed was described as an anaesthetic in Avicenna's The Canon of Medicine, which served as an authoritative medical textbook, and the seed of ordinary lettuce, Lactuca sativa, is still used in Avicenna's native Iran as a folk medicine.

Lactucopicrin, also known by the synonym intybin, was first identified as one of the bitter principles in the milky latex of wild lettuce (Lactuca virosa), known as lactucarium, which has been collected and used medicinally since the mid-19th century. The latex was traditionally obtained by incising the stems of mature plants and drying the exuded fluid.

A comprehensive pharmacological study published in 1911 revealed that the fresh latex contained two key bitter principles responsible for its sedative and analgesic properties: lactucin and lactucopicrin. These compounds were characterized as the primary contributors to the central nervous system effects observed in lactucarium preparations.

19th and Early 20th Century Pharmaceutical Use

Lactucarium is described and standardized in the 1898 United States Pharmacopoeia and 1911 British Pharmaceutical Codex for use in lozenges, tinctures, and syrups as a sedative for irritable cough or as a mild hypnotic (sleeping aid) for insomnia. The standard definition of lactucarium in these codices required its production from Lactuca virosa, but it was recognized that smaller quantities of lactucarium could be produced in a similar way from Lactuca sativa and Lactuca canadensis var. elongata, and even that lettuce-opium obtained from Lactuca serriola or Lactuca quercina was of superior quality.

Wild lettuce has a long medicinal history. In the 19th century, doctors and pharmacists dried the milky sap into a dark, resinous substance called lactucarium, which was used as a mild substitute for opium. In the 19th century, wild lettuce gained popularity in Europe and North America as an herbal remedy for coughs, insomnia, and nervousness.

Traditional Use Against Malaria: Afghan Folk Medicine

Folklore reports from Afghanistan prior to the wars described the use of aqueous root extracts of Cichorium intybus (L.) as a light-sensitive plant remedy for malaria. In the mid-1970s, a report of a successful, light-sensitive plant remedy for malaria used in western Afghanistan was described in detail. Plants were collected in the evening, had the tops removed and discarded, the roots washed, and multiple incisions made laterally around each root. The splayed roots were then placed in a shallow pan of water to remain soaking in the dark, and the entire aqueous extract was to be drunk just before dawn. This photosensitive preparation was specifically designed to preserve the light-labile sesquiterpene lactones later identified as lactucin and lactucopicrin.

Traditional Use as a Digestive Bitter

Chicory root is a rich source of bitter-tasting sesquiterpene lactones, which promote appetite and digestion. The broader ethnomedicinal context of plants containing lactucopicrin includes their use across the Mediterranean, Central Asia, and Europe as digestive tonics, and in traditional European phytotherapy as remedies for liver complaints and rheumatic conditions.

4. Biosynthesis and Chemistry

Biosynthetic Pathway

Subsequent oxidation of germacrene A to germacrene A acid (GAA) is catalyzed by germacrene A oxidase (GAO), a cytochrome P450 enzyme (CYP71AV subfamily), with homologs like LsGAO identified in lettuce. The carboxylic acid group in GAA then undergoes regioselective hydroxylation and lactonization by costunolide synthase (COS, CYP71BL2). This biochemical cascade — involving sesquiterpene synthases and P450 enzymes — proceeds from the universal terpenoid precursors through a guaianolide scaffold before further decorations yield the final lactucopicrin structure. Both sesquiterpene synthases and P450s are supergene families widely present in bacteria, fungi, and plants, and they play critical roles in generating terpenoid diversity in nature. Specifically, the coordinated reactions of these enzyme families synthesize activated terpenoid backbones on which other chemical decorations — such as acetylation, methylation, lipidation, and further oxidations — occur to increase chemical diversity.

5. Key Active Compounds and Mechanisms of Action

The α-Methylene-γ-Lactone Moiety

The pharmacological reactivity of lactucopicrin is substantially attributed to its α-methylene-γ-lactone (exocyclic methylene adjacent to the lactone carbonyl) functional group — a structural feature shared by many bioactive sesquiterpene lactones. The ability of sesquiterpene lactones to bind covalently with biological macromolecules is the basis of both their biological activity and their allergenicity. This electrophilic moiety undergoes Michael-type additions with thiol groups on cysteine residues of proteins, which underlies many of the compound's downstream effects on transcription factor activity and enzyme inhibition.

NF-κB and AHR Pathway Modulation

Using a TNFα-induced inflammation model in macrophages, endothelial, and intestinal epithelial cells, lactucopicrin was identified as a potent NF-κB antagonist. In silico docking and functional assays revealed lactucopicrin as a novel AHR (aryl hydrocarbon receptor) modulator. Crucially, silencing AHR expression attenuated lactucopicrin-mediated NF-κB inhibition, uncovering a previously unrecognized AHR-NF-κB crosstalk mechanism.

In tumor necrosis factor-α-stimulated human or mouse aortic endothelial cells, lactucopicrin dose-dependently inhibited NF-κB activation, and concomitantly repressed both vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1)-mediated monocyte adhesion. The lactucopicrin effect was not due to modulation of inhibitor of NF-κB kinases (IKK) α/β/γ, inhibitor of NF-κB alpha (IκBα), and NF-κB/p65 DNA binding activity. A separate study found that the mechanism instead operates through suppression of importin-α3 expression, which is required for nuclear translocation of NF-κB.

Acetylcholinesterase Inhibition

Lactucopicrin has been shown to act as an acetylcholinesterase inhibitor. Lactucopicrin inhibits acetylcholinesterase (AChE) with an IC₅₀ of 150.3 μM. Acetylcholinesterase inhibition prevents the breakdown of the neurotransmitter acetylcholine in synaptic clefts, a mechanism relevant to both CNS sedation and potential neuroprotective applications.

Atheroprotective Mechanism: LOX-1 and Lipid Rafts

Lactucopicrin at physiologically reachable concentrations inhibits oxidized low-density lipoprotein (oxLDL)-induced foam cell formation in inflammatory mouse bone marrow-derived macrophages. This effect is not due to modulation of cholesterol efflux, but is reliant on a reduction in lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1)-mediated cholesterol influx. Lactucopicrin does not affect LOX-1 expression, cellular oxidative stress, and exocytosis — known mechanisms regulating LOX-1 function in cholesterol influx. Strikingly, lactucopicrin selectively decreases LOX-1 content in lipid rafts, an effect responsible for the lactucopicrin effect on cholesterol influx.

Anticancer Mechanisms (Preclinical)

Daily administration of lactucopicrin showed a dose- and time-dependent reduction of glioblastoma (U87Mg) cell growth and viability, also confirmed by inhibition of clonogenic potential and mobility of U87Mg cells. Lactucopicrin activated autophagy in U87Mg cells and decreased the phosphorylation of proliferative signals pAKT and pERK. Lactucopicrin also induced cell cycle arrest in G2/M phase, confirmed by decrease of CDK2 protein and increase of p53 and p21. Lactucopicrin stimulated apoptosis as evidenced by reduction of procaspase 6 and the increase of the cleaved/full-length PARP ratio.

Anticancer action of lactucopicrin in SKMEL-5 human skin cancer cells was reported to be mediated via apoptosis induction, G2/M cell cycle arrest, and downregulation of the mTOR/PI3K/AKT signalling pathway (published in J. BUON, 2018). Growth inhibition of Saos-2 osteosarcoma cells by lactucopicrin was reported to be mediated via inhibition of cell migration and invasion, sub-G1 cell cycle disruption, apoptosis induction, and Raf signalling.

6. Scientific Evidence by Area of Application

6.1 Analgesic and Sedative Effects

Evidence level: Animal (in vivo), no human clinical trials directly on isolated lactucopicrin.

Lactucin and its derivative lactucopicrin, which are characteristic bitter sesquiterpene lactones of Lactuca virosa and Cichorium intybus, were evaluated for analgesic and sedative properties in mice. The compounds showed analgesic effects at doses of 15 and 30 mg/kg in the hot plate test similar to that of ibuprofen, used as a standard drug, at a dose of 30 mg/kg. The analgesic activities of the compounds at a dose of 30 mg/kg in the tail-flick test were comparable to that of ibuprofen given at a dose of 60 mg/kg. Lactucopicrin appeared to be the most potent analgesic of the three tested compounds.

Lactucin and lactucopicrin, but not 11β,13-dihydrolactucin, also showed sedative properties in the spontaneous locomotor activity test. This specificity for lactucopicrin over a close structural analogue strongly suggests that the analgesic and sedative activities are related to specific structural features of lactucopicrin and lactucin rather than a generalized class effect.

Animal studies have confirmed that both lactucin and lactucopicrin produce measurable sedative effects, while a closely related compound in the same plant showed no sedative activity at all, even at higher doses. This suggests the sedative properties are specific to these two chemicals rather than a general effect of the plant. These findings come from lab and animal research. No large, rigorous clinical trials in humans have confirmed specific doses or reliable effects.

The analgesic mechanism is not fully elucidated. Research into lactucin and lactucopicrin has demonstrated measurable analgesic and sedative activity in animal models, suggesting central nervous system activity without the respiratory depression associated with opiates. The acetylcholinesterase inhibitory activity of lactucopicrin may contribute to CNS effects, though the precise receptor-level mechanism for its analgesic action remains under investigation.

With the recent exception of a small study on insomnia in pregnant women (involving the broader lactucarium preparation, not isolated lactucopicrin), there is little clinical evidence to support use for other indications. There is limited clinical evidence to support specific dose recommendations for humans. Doses of 1,000 mg of lettuce seed have been used for periods of up to 2 weeks in one small double-blind randomized placebo-controlled trial. This trial evaluated the broad seed preparation, not purified lactucopicrin.

6.2 Anti-Inflammatory Effects

Evidence level: In vitro (cell-based) and animal (in vivo), no human clinical trials on isolated lactucopicrin.

A 2025 study investigated the anti-inflammatory properties of sesquiterpene lactones derived from Cichorium intybus L. (chicory), focusing on their modulation of NF-κB and AHR signaling pathways. Using a TNFα-induced inflammation model in macrophages, endothelial, and intestinal epithelial cells, lactucopicrin was identified as a potent NF-κB antagonist. In silico docking and functional assays revealed lactucopicrin as a novel AHR modulator. Crucially, silencing AHR expression attenuated lactucopicrin-mediated NF-κB inhibition, uncovering a previously unrecognized AHR-NF-κB crosstalk mechanism.

In TNF-α-stimulated endothelial cells, lactucopicrin inhibited importin-α3 expression and concomitantly suppressed NF-κB activation and the subsequent VCAM-1 and ICAM-1 expression. This event led to an appreciable reduction in monocyte adhesion to activated endothelial cells. These effects are of theoretical relevance to vascular inflammatory diseases. All findings to date remain at the preclinical level.

6.3 Antimalarial Activity

Evidence level: In vitro only; no human clinical trials.

Preparative isolation and bioassay against the HB3 clone of strain Honduras-1 of Plasmodium falciparum identified the previously known light-sensitive sesquiterpene lactones lactucin and lactucopicrin to be antimalarial compounds. There are at least two antimalarial compounds in Cichorium intybus, identified as lactucin and lactucopicrin, which had both been previously reported in chicory, but whose antimalarial activity had not been previously documented.

Lactucopicrin, lactucin, and guaianolide sesquiterpenes isolated from Cichorium intybus root aqueous extract possessed anti-plasmodial activity. Lactucopicrin at a concentration of 50 μg/mL completely inhibited P. falciparum in the in vitro bioassay. This work validated the traditional Afghan folk medicine use of chicory root preparations against malaria. No human clinical trials have evaluated lactucopicrin for malaria treatment.

6.4 Cardiovascular and Atheroprotective Effects

Evidence level: In vitro (macrophage models) and animal (ApoE⁻/⁻ mouse); no human clinical trials.

Lactucopicrin limits macrophage foam cell formation through a reduction of LOX-1 distribution in lipid rafts, thus contributing to its atheroprotective effect. ApoE⁻/⁻ mice fed a high-fat diet supplemented with lactucopicrin for 12 weeks were evaluated in this study, which demonstrated an in vivo atheroprotective signal in an animal model of atherosclerosis. The specific outcomes in those treated mice relative to controls (including plaque area measurements) are documented in the primary publication (Molecular Nutrition & Food Research, 2022).

Sesquiterpene lactone-rich Brussels/witloof chicory, one variety of chicory, has been found to slow down the progression of established atherosclerosis in mice. These are preclinical findings and have not been replicated in human trials.

6.5 Anticancer Activity

Evidence level: In vitro (cell lines) only; no animal or human clinical trials on lactucopicrin specifically.

Research on lactucopicrin's anticancer potential spans multiple cancer cell lines, all conducted in vitro. A study proposed lactucopicrin (LCTP), a natural sesquiterpene lactone from Lactuca virosa, as a molecule able to control the growth of glioblastoma continuous cell line U87Mg. The IC₅₀ of U87Mg against LCTP revealed a strong cytotoxic effect. Daily administration of LCTP showed a dose- and time-dependent reduction of GBM cell growth and viability.

In human melanoma (SKMEL-5) cells, anticancer activity was attributed to apoptosis induction, G2/M cell cycle arrest, and downregulation of the mTOR/PI3K/AKT signaling pathway. In osteosarcoma (Saos-2) cells, inhibition of cell migration and invasion, sub-G1 cell cycle disruption, and apoptosis induction via Raf signaling were reported. All of these findings are in vitro only and carry significant uncertainty regarding translation to clinical oncology settings.

6.6 Gut Microbiota Metabolism and Bioavailability

Evidence level: Human in vitro fermentation and urine metabolomics (1 study); human pharmacokinetic data from chicory preparations.

Gut microbiota converts dietary phytochemicals into metabolites and modulates their health effects. The microbial metabolism of dietary terpenoids, such as the sesquiterpene lactones of leafy vegetables, was previously unknown. In vitro fermentation of lactucopicrin, lactucin, and romaine lettuce with gut microbiota from independent donors showed extensive metabolism through untargeted metabolomics. Dehydroxylations and double bond hydrogenations are the main catabolic reactions. Isomers of dihydrolactucopicrin, tetrahydrolactucopicrin, and deoxylactucin are observed after lactucopicrin metabolism.

Phase II conjugates of most of these metabolites are detected in the urine of healthy volunteers after escarole salad intake. Glucuronides and sulfates of dihydrolactucopicrin, tetrahydrolactucopicrin, dihydrolactucin, and deoxylactucin are detected in the urine, although with large inter-subject variability. This is the first report on the gut microbiota metabolism of sesquiterpene lactones in humans.

The recovery of total sesquiterpene lactones in blood, urine, and feces was 7.03%, 1.13%, and 43.76% of the ingested dose, respectively. Human fecal suspensions with intestinal microbiota degraded glycosylated sesquiterpene lactones in chicory, and converted lactucopicrin and 11β,13-dihydrolactucopicrin to lactucin and 11β,13-dihydrolactucin, respectively. Collectively, Brussels/witloof chicory sesquiterpene lactones are poorly bioavailable and undergo partial gut microbial and phase II metabolism in humans.

A significant obstacle limiting the pharmacological use of lactucopicrin is its poor aqueous solubility and low oral bioavailability, which may necessitate higher doses and increase systemic toxicity. Following oral consumption of chicory preparations, a human pharmacokinetic study confirmed that only lactucin and dihydrolactucin were detected in circulation at low concentrations, while in vitro fermentation assays demonstrated the conversion of lactucopicrin and lactucin into lactucin-type compounds by the gut microbiota.

7. Body Systems and Health Areas of Association

• Central Nervous System: Lactucopicrin is a bitter substance with sedative and analgesic effects acting on the central nervous system. Acetylcholinesterase inhibitory activity may be relevant to cholinergic neurotransmission.
• Cardiovascular System: Preclinical evidence suggests atheroprotective effects through reduction of macrophage foam cell formation via LOX-1/lipid raft modulation, and anti-inflammatory effects on vascular endothelial cells via suppression of VCAM-1 and ICAM-1.
• Immune and Inflammatory System: Using a TNFα-induced inflammation model, lactucopicrin was identified as a potent NF-κB antagonist. In silico docking and functional assays revealed lactucopicrin as a novel AHR modulator. Silencing AHR expression attenuated lactucopicrin-mediated NF-κB inhibition, uncovering a previously unrecognized AHR-NF-κB crosstalk mechanism.
• Gastrointestinal System: As a bitter compound, lactucopicrin participates in the traditional role of Asteraceae bitter preparations in stimulating digestive secretions. Substantial gut microbial catabolism of lactucopicrin shapes its ultimate bioavailability and metabolite profile.
• Anti-Infective / Parasitic: In vitro antimalarial activity against Plasmodium falciparum has been demonstrated, consistent with traditional use of chicory root preparations in malaria-endemic regions.
• Oncology (preclinical only): In vitro antiproliferative activity demonstrated in glioblastoma, melanoma, and osteosarcoma cell lines via shared mechanisms of apoptosis induction, cell cycle arrest, and inhibition of pro-survival kinase pathways.

8. Dosage Forms and Reported Dosages

Lactucopicrin as an isolated, purified compound is not available in standardized commercial dietary supplement form. It is encountered as a component of whole plant preparations derived from its botanical sources. The following dosages appear in the scientific literature:

• Animal analgesic/sedative studies: Lactucopicrin exhibits sedative and analgesic effects on the central nervous system, as demonstrated in mouse models at doses of 15–30 mg/kg intraperitoneally.
• Ibuprofen-comparable analgesia (mice): The compounds showed analgesic effects at doses of 15 and 30 mg/kg in the hot plate test similar to that of ibuprofen at a dose of 30 mg/kg. The analgesic activities of the compounds at a dose of 30 mg/kg in the tail-flick test were comparable to that of ibuprofen given at a dose of 60 mg/kg. These are intraperitoneal mouse doses and cannot be directly extrapolated to human oral dosing.
• In vitro antimalarial: Lactucopicrin displays antimalarial properties by preventing parasite growth in vitro at 50 μg/L over 48 hours.
• Human pharmacokinetic study (chicory preparation): The recovery of total sesquiterpene lactones in blood, urine, and feces was 7.03%, 1.13%, and 43.76% of the ingested dose, respectively, in a human pharmacokinetic study using Brussels/witloof chicory, though the exact milligram dose of isolated lactucopicrin in that preparation was not separately reported as a standalone figure in available summaries.
• Human trial using whole preparation: Doses of 1,000 mg of lettuce seed have been used for periods of up to 2 weeks in one small double-blind randomized placebo-controlled trial addressing insomnia; isolated lactucopicrin dose was not specified.

No established human dose for purified lactucopicrin has been determined in clinical research. Poor aqueous solubility and low oral bioavailability may necessitate higher doses and increase systemic toxicity.

9. Safety Considerations and Interactions

Allergic Contact Dermatitis

The ability of sesquiterpene lactones to bind covalently with biological macromolecules is the basis of their allergenicity. Contact sensitization to allergenic sesquiterpene lactones may imply contact allergy to plants that are consumed either as vegetables, spices, teas, or herbal remedies. This may cause systemic allergic contact dermatitis, which is most frequently reported to be caused by metals, drugs, and plants/herbals.

Lettuce, including butterhead lettuce and romaine lettuce, contains sesquiterpene lactones such as lactucin, lactucopicrin, and their derivatives. Handling of lettuce could cause occupational allergic contact dermatitis in sensitized gardeners, kitchen personnel, or other food handlers. Concomitant immediate hypersensitivity has been reported in a few of these patients, mainly presenting as protein contact dermatitis and/or contact urticaria.

Almost 50% of sesquiterpene lactones are potential contact allergens. The structural features responsible — notably the α-methylene-γ-lactone group — are shared by lactucopicrin. The most important allergens in the Compositae (Asteraceae) family are sesquiterpene lactones, which are present in the oleoresin fraction of leaf, stem, flower, and possibly in the pollen.

Cross-Reactivity Within Asteraceae

Patients with contact allergy to sesquiterpene lactones are usually hypersensitive to Asteraceae plant products such as herbal teas. Individuals with known sensitization to other Asteraceae (e.g., chamomile, arnica, or chrysanthemum) may be at elevated risk of cross-reaction to lactucopicrin-containing preparations.

Oral Bioavailability and Systemic Toxicity Concerns

A significant obstacle limiting the pharmacological use of lactucopicrin is its poor aqueous solubility and low oral bioavailability, which may necessitate higher doses and increase systemic toxicity. The α-methylene-γ-lactone moiety, while central to bioactivity, is also responsible for nonselective covalent reactivity with biological thiols, including those in glutathione and cellular proteins, raising potential toxicological concerns at supraphysiological concentrations.

Metabolic Conversion and Inter-Individual Variability

Glucuronides and sulfates of dihydrolactucopicrin, tetrahydrolactucopicrin, dihydrolactucin, and deoxylactucin are detected in the urine of healthy volunteers, although with large inter-subject variability. This inter-individual variability in metabolic conversion by the gut microbiota means that the effective systemic exposure to lactucopicrin and its metabolites may differ substantially between individuals consuming the same dose.

Light Sensitivity

Lactucopicrin is noted for its potent bitterness and light sensitivity. Preparations containing lactucopicrin can degrade on exposure to light, potentially reducing potency of botanical preparations stored without light protection. The traditional Afghan antimalarial preparation explicitly required dark storage and consumption just before dawn, reflecting empirical recognition of this photolability.

Absence of Human Clinical Safety Data

No dedicated human clinical safety trials for isolated lactucopicrin have been published in the indexed literature. The compound's presence in commonly consumed foods (lettuce, chicory, escarole) establishes a general dietary exposure history, but the safety profile at supplemental or therapeutic doses in isolated form is not established. In the twentieth century, two major studies found commercial lactucarium to be without effect — a finding that reflects both the potency questions of processed preparations and the absence of rigorously demonstrated clinical benefit at doses achievable through traditional preparations.

10. Summary of Evidence Landscape

Lactucopicrin is a well-characterized plant secondary metabolite with a robust phytochemical identity and a multimillennial history of use in the context of its source plants. The scientific literature supports several plausible mechanisms of action — particularly NF-κB/AHR anti-inflammatory modulation, acetylcholinesterase inhibition, LOX-1/lipid raft-mediated atheroprotection, and antimalarial activity against P. falciparum — that are scientifically credible and mechanistically coherent. However, the totality of this evidence is predominantly preclinical (in vitro cell studies and rodent models), with very limited human data. Human pharmacokinetic studies have shown that lactucopicrin itself has poor oral bioavailability and is substantially metabolized by gut microbiota before reaching systemic circulation, complicating translation of preclinical findings. No randomized controlled clinical trials in humans have been conducted using isolated, purified lactucopicrin for any indication. The compound therefore remains in the domain of active early-phase research rather than evidence-based clinical application.

References

• Ávila-Gálvez MÁ, et al. "Lactucopicrin: A Sesquiterpene Lactone with Anti-Inflammatory Activity Modulates the Crosstalk between NF-kB and AHR Pathways." Journal of Medicinal Chemistry, ACS Publications, 2025.
• Ávila-Gálvez MÁ, et al. "Lactucopicrin: A Sesquiterpene Lactone with Anti-Inflammatory Activity Modulates the Crosstalk between NF-kB and AHR Pathways." PMC Full Text, 2025.
• Weng H, He L, et al. "Natural lactucopicrin alleviates importin-α3-mediated NF-κB activation in inflammated endothelial cells and improves sepsis in mice." Biochemical Pharmacology, 2021.
• Li Q, et al. "Terpene Lactucopicrin Limits Macrophage Foam Cell Formation by a Reduction of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 in Lipid Rafts." Molecular Nutrition & Food Research, 2022.
• Wesołowska A, Nikiforuk A, Michalska K, Kisiel W, Chojnacka-Wójcik E. "Analgesic and sedative activities of lactucin and some lactucin-like guaianolides in mice." Journal of Ethnopharmacology, 2006.
• Bischoff TA, Kelley CJ, Karchesy Y, et al. "Antimalarial activity of lactucin and lactucopicrin: sesquiterpene lactones isolated from Cichorium intybus L." Journal of Ethnopharmacology, 2004.
• García CJ, Beltrán D, Tomás-Barberán FA. "Human Gut Microbiota Metabolism of Dietary Sesquiterpene Lactones: Untargeted Metabolomics Study of Lactucopicrin and Lactucin Conversion In Vitro and In Vivo." Molecular Nutrition & Food Research, 2020.
• Low Oral Bioavailability and Partial Gut Microbiotic and Phase II Metabolism of Brussels/Witloof Chicory Sesquiterpene Lactones in Healthy Humans. PMC, 2021.
• Rotondo et al. "Implication of Lactucopicrin in Autophagy, Cell Cycle Arrest and Oxidative Stress to Inhibit U87Mg Glioblastoma Cell Growth." PMC, 2020.
• Wikipedia. "Lactucopicrin." Wikimedia Foundation.
• Wikipedia. "Lactucarium." Wikimedia Foundation.
• ScienceDirect Topics. "Lactucopicrin — an overview."
• Ghantous A, et al. "Sesquiterpenoids Lactones: Benefits to Plants and People." PMC, 2013.
• Bouwmeester H, et al. "Sesquiterpene Lactones – Insights into Biosynthesis, Regulation and Signalling Roles." Critical Reviews in Plant Sciences, 2024.
• Obermeyer et al. "Lettuce Anaphylaxis in a Florist With Hand Dermatitis and Contact Allergy to the Compositae (Asteraceae) Family of Plants." Contact Dermatitis, 2025.
• Paulsen E. "Systemic allergic dermatitis caused by sesquiterpene lactones." Contact Dermatitis, 2017.
• Antosik-Wójcińska AZ, et al. "Asteraceae species as potential environmental factors of allergy." PMC, 2019.
• Drugs.com. "Lettuce Opium Uses, Benefits & Dosage." (Medically reviewed, updated 2025.)
• Phytochemical Profile and Analgesic Properties of Chicory Root Extract in the Hot-Plate Test in Mice. International Journal of Molecular Sciences, 2025.